Pomalidomide is a new immunomodulatory drug used for treatment of relapsed/refractory plasma cell myeloma (PCM). In this paper, we describe a case report of a patient with relapsed PCM was subsequently treated with pomalidomide.Pomalidomid jest nowym lekiem immunomodulującym stosowanym w terapii nawrotowego/opornego szpiczaka plazmocytowego (PCM). W niniejszej pracy przedstawiono przypadek chorego na nawrotowego PCM leczonego pomalidomidem
Multiple myeloma (MM) is a malignant and still incurable proliferative disease of the hematopoietic ...
Although survival of multiple myeloma patients has at least doubled during recent years, most patien...
Wprowadzenie inhibitorów kinaz tyrozynowych (TKI) do leczenia chorych na przewlekłą białaczką szpiko...
W ostatnich latach dokonał się znaczący postęp w leczeniu szpiczaka plazmocytowego (PCM). Dzięki now...
Pomalidomide is a new immunomodulatory drug used for treatment of plasma cell myeloma (PCM). In this...
The article is dedicated to pomalidomide efficacy in heavily pretreated patient with a long term his...
The case report presents IgA plasma cell myeloma patient treated with chemotherapy, botrezomib,autol...
Niewydolność nerek pogarsza rokowanie chorych na szpiczaka plazmocytowego (PCM). W artykule przedsta...
During nearly two decades there has been continuous progress in the therapy of plasma cell myeloma r...
Induction treatment of patients with plasma cell myeloma (PCM) is based on the novel agent: immunomo...
Introduction of new drugs into therapy of multiple myeloma prolonged significantly progression free ...
Understanding of the biology of plasma cell myeloma (PCM) and the introduction of new drugs for the ...
We present a case of 69 year-old woman with plasma cell myeloma who relapsed after autologous hemato...
Ruxolitinib is the first JAK kinase inhibitor registered for the treatment of primary myelofibrosis ...
Ipilimumab jest lekiem immunologicznym, należącym do nowej grupy immunoterapii typu „checkpoints”, k...
Multiple myeloma (MM) is a malignant and still incurable proliferative disease of the hematopoietic ...
Although survival of multiple myeloma patients has at least doubled during recent years, most patien...
Wprowadzenie inhibitorów kinaz tyrozynowych (TKI) do leczenia chorych na przewlekłą białaczką szpiko...
W ostatnich latach dokonał się znaczący postęp w leczeniu szpiczaka plazmocytowego (PCM). Dzięki now...
Pomalidomide is a new immunomodulatory drug used for treatment of plasma cell myeloma (PCM). In this...
The article is dedicated to pomalidomide efficacy in heavily pretreated patient with a long term his...
The case report presents IgA plasma cell myeloma patient treated with chemotherapy, botrezomib,autol...
Niewydolność nerek pogarsza rokowanie chorych na szpiczaka plazmocytowego (PCM). W artykule przedsta...
During nearly two decades there has been continuous progress in the therapy of plasma cell myeloma r...
Induction treatment of patients with plasma cell myeloma (PCM) is based on the novel agent: immunomo...
Introduction of new drugs into therapy of multiple myeloma prolonged significantly progression free ...
Understanding of the biology of plasma cell myeloma (PCM) and the introduction of new drugs for the ...
We present a case of 69 year-old woman with plasma cell myeloma who relapsed after autologous hemato...
Ruxolitinib is the first JAK kinase inhibitor registered for the treatment of primary myelofibrosis ...
Ipilimumab jest lekiem immunologicznym, należącym do nowej grupy immunoterapii typu „checkpoints”, k...
Multiple myeloma (MM) is a malignant and still incurable proliferative disease of the hematopoietic ...
Although survival of multiple myeloma patients has at least doubled during recent years, most patien...
Wprowadzenie inhibitorów kinaz tyrozynowych (TKI) do leczenia chorych na przewlekłą białaczką szpiko...